G1 Therapeutics Announces Top Line Results from Pivotal Phase 3 Trial of Trilaciclib in Patients Receiving Triplet Therapy with FOLFOXIRI Bevacizumab for Metastatic Colorectal Cancer (CRC) (PRESERVE 1)

Source: Nasdaq GlobeNewswire / 13 Feb 2023 05:00:38   America/Chicago